Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatr Clin North Am. 2014 Sep;37(3):375-91. doi: 10.1016/j.psc.2014.05.006. Epub 2014 Jul 24.

Pharmacological treatment of obsessive-compulsive disorder.

Author information

1
Department of Psychiatry and Child Study Center, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA. Electronic address: Christopher.pittenger@yale.edu.
2
Department of Psychiatry and Child Study Center, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA.

Abstract

Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.

KEYWORDS:

Antidepressant; Augmentation; OCD; Obsessive-compulsive disorder; Pharmacotherapy; SSRI

PMID:
25150568
PMCID:
PMC4143776
DOI:
10.1016/j.psc.2014.05.006
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center